417 related articles for article (PubMed ID: 32198351)
1. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
von Roemeling CA; Wang Y; Qie Y; Yuan H; Zhao H; Liu X; Yang Z; Yang M; Deng W; Bruno KA; Chan CK; Lee AS; Rosenfeld SS; Yun K; Johnson AJ; Mitchell DA; Jiang W; Kim BYS
Nat Commun; 2020 Mar; 11(1):1508. PubMed ID: 32198351
[TBL] [Abstract][Full Text] [Related]
2. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
3. Blocking CD47 promotes antitumour immunity through CD103
Wang S; Wu Q; Chen T; Su R; Pan C; Qian J; Huang H; Yin S; Xie H; Zhou L; Zheng S
J Hepatol; 2022 Aug; 77(2):467-478. PubMed ID: 35367532
[TBL] [Abstract][Full Text] [Related]
4. Phagocytosis checkpoints as new targets for cancer immunotherapy.
Feng M; Jiang W; Kim BYS; Zhang CC; Fu YX; Weissman IL
Nat Rev Cancer; 2019 Oct; 19(10):568-586. PubMed ID: 31462760
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection.
Cham LB; Torrez Dulgeroff LB; Tal MC; Adomati T; Li F; Bhat H; Huang A; Lang PA; Moreno ME; Rivera JM; Galkina SA; Kosikova G; Stoddart CA; McCune JM; Myers LM; Weissman IL; Lang KS; Hasenkrug KJ
Cell Rep; 2020 Apr; 31(2):107494. PubMed ID: 32294445
[TBL] [Abstract][Full Text] [Related]
6. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
7. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
9. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
Liu X; Liu L; Ren Z; Yang K; Xu H; Luan Y; Fu K; Guo J; Peng H; Zhu M; Fu YX
Cell Rep; 2018 Aug; 24(8):2101-2111. PubMed ID: 30134171
[TBL] [Abstract][Full Text] [Related]
10. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
11. Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity.
Anghelina D; Lam E; Falck-Pedersen E
J Virol; 2016 Jul; 90(13):5915-27. PubMed ID: 27076643
[TBL] [Abstract][Full Text] [Related]
12. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition.
Tal MC; Torrez Dulgeroff LB; Myers L; Cham LB; Mayer-Barber KD; Bohrer AC; Castro E; Yiu YY; Lopez Angel C; Pham E; Carmody AB; Messer RJ; Gars E; Kortmann J; Markovic M; Hasenkrug M; Peterson KE; Winkler CW; Woods TA; Hansen P; Galloway S; Wagh D; Fram BJ; Nguyen T; Corey D; Kalluru RS; Banaei N; Rajadas J; Monack DM; Ahmed A; Sahoo D; Davis MM; Glenn JS; Adomati T; Lang KS; Weissman IL; Hasenkrug KJ
mBio; 2020 Jun; 11(3):. PubMed ID: 32576678
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles.
Li X; Khorsandi S; Wang Y; Santelli J; Huntoon K; Nguyen N; Yang M; Lee D; Lu Y; Gao R; Kim BYS; de Gracia Lux C; Mattrey RF; Jiang W; Lux J
Nat Nanotechnol; 2022 Aug; 17(8):891-899. PubMed ID: 35637356
[TBL] [Abstract][Full Text] [Related]
16. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
18. Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity.
Choi Y; Nam GH; Kim GB; Kim S; Kim YK; Kim SA; Kim HJ; Lee EJ; Kim IS
Cancer Gene Ther; 2021 Sep; 28(9):960-970. PubMed ID: 34349240
[TBL] [Abstract][Full Text] [Related]
19. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
[TBL] [Abstract][Full Text] [Related]
20. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
